Drug Trial Radar · NCT06310616
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Mar 6, 2024
Primary completion
Aug 15, 2024
Study completion Aug 15, 2024
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female participants.
Conditions
- HIV Infections
Interventions
VH4524184Drug
VH4524184 will be administered.
LoestrinDrug
Loestrin will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve (AUC) from time zero (pre-dose) to the end of the dosing interval at steady state (AUC0-Tau, ss) of EE and NEA without coadministration with VH4524184Time frame: On Day 10
- AUC0-Tau, ss of EE and NEA with coadministration with VH4524184Time frame: On Day 20
- Maximum plasma concentration (Cmax) for EE and NEA without coadministration with VH4524184Time frame: On Day 10
- Cmax for EE and NEA with coadministration with VH4524184Time frame: On Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.